Mark Leibowitz

989 citations

16 papers · 522 indexed · h-index 11

Impact in

Pharmacology top 5%
- Cholinesterase and Neurodegenerative Diseases
- Treatment of Major Depression
- Pharmacology and Obesity Treatment
Psychiatry and Mental health top 10%

Papers in ⓘ

Anesthesiology and Pain Medicine 2
- Pain Management and Opioid Use 2
Pharmacology 5
- Cholinesterase and Neurodegenerative Diseases 2
- Pharmacology and Obesity Treatment 2

Co-authors: Larry Ereshefsky (5 shared papers)S. S. Jhee (4 shared papers)Heinz Schmidli (1 shared paper)F. Pommier (1 shared paper)Albert Enz (1 shared paper)Gilbert Lefèvre (1 shared paper)G Sędek (1 shared paper)Silke Appel‐Dingemanse (1 shared paper)
Journals: Journal of Cardiovascular Pharmacology (2 papers)The Journal of Clinical Pharmacology (2 papers)Neurology (2 papers)Clinical Therapeutics (2 papers)Alzheimer s & Dementia (1 paper)
Partner nations: United States United Kingdom Switzerland

In The Last Decade

Mark Leibowitz

16 papers receiving 502 citations

Peers

Countries citing papers authored by Mark Leibowitz

Since Specialization

Citations

This map shows the geographic impact of Mark Leibowitz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Leibowitz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Leibowitz more than expected).

Fields of papers citing papers by Mark Leibowitz

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Leibowitz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Leibowitz. The network helps show where Mark Leibowitz may publish in the future.

Co-authors

The 25 scholars most cited alongside Mark Leibowitz, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Mark Leibowitz Line = papers co-authored together Mark Leibowitz links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

#	Work
1	Pharmacokinetics and Pharmacodynamics of the Novel Daily Rivastigmine Transdermal Patch Compared With Twice-daily Capsules in Alzheimer's Disease Patients Clinical Pharmacology & Therapeutics ·Gilbert Lefèvre, G Sędek, S. S. Jhee, Mark Leibowitz, H-La Huang, Albert Enz, Steve Maton, Larry Ereshefsky, F. Pommier, Heinz Schmidli, Silke Appel‐Dingemanse	2007	106
2	Gender and pramipexole effects on levodopa pharmacokinetics and pharmacodynamics Neurology ·Katie Kompoliti, Charles H. Adler, Rema Raman, Jonathan H. Pincus, Mark Leibowitz, James J. Ferry, Lucy M. Blasucci, John N. Caviness, Sue E. Leurgans, W. M. Chase, L. C. Yones, Ern Yu Tan, Paul M. Carvey, Christopher G. Goetz	2002	62
3	QT Effects of Duloxetine at Supratherapeutic Doses: A Placebo and Positive Controlled Study Journal of Cardiovascular Pharmacology ·Lu Zhang, Jill Chappell, Celedon Gonzales, David S. Small, Mary Pat Knadler, JT Callaghan, Jennie Francis, D. Desaiah, Mark Leibowitz, Larry Ereshefsky, David Hoelscher, Philip T. Leese, Michael A. Derby	2007	52
4	Single‐Dose Administration of MK‐0657, an NR2B‐Selective NMDA Antagonist, Does Not Result in Clinically Meaningful Improvement in Motor Function in Patients With Moderate Parkinson's Disease The Journal of Clinical Pharmacology ·Carol Addy, C. Assaid, David Hreniuk, Mark Stroh, Yang Xu, W. Joseph Herring, Aaron Ellenbogen, Hyder A. Jinnah, Louis Kirby, Mark Leibowitz, R. Malcolm Stewart, Daniel Tarsy, James W. Tetrud, S. Aubrey Stoch, Keith Gottesdiener, John A. Wagner	2009	51
5	Low Penetration of Oseltamivir and Its Carboxylate into Cerebrospinal Fluid in Healthy Japanese and Caucasian Volunteers Antimicrobial Agents and Chemotherapy ·S. S. Jhee, Mark Yen, Larry Ereshefsky, Mark Leibowitz, M. Schulte, Benoite Kaeser, Lauren Boak, Anand C. Patel, Gerhard Hoffmann, E. Prinssen, Craig R. Rayner	2008	47
6	Efficacy and safety of sibutramine for weight loss in obese patients with hypertension well controlled by β-adrenergic blocking agents: a placebo-controlled, double-blind, randomised trial Journal of Human Hypertension ·John J. Sramek, Mark Leibowitz, Samuel Weinstein, Everton Rowe, Carl M. Mendel, Brian Levy, F. Gilbert McMahon, William S. Mullican, Phillip D. Toth, Neal R. Cutler	2002	43
7	Effects of encapsulation on absorption of sumatriptan tablets: data from healthy volunteers and patients during a migraine Clinical Therapeutics ·Eliane Fuseau, Olivier Pétricoul, Antony Sabin, Adrian Pereira, Stephen O’Quinn, Stephen Thein, Mark Leibowitz, Helen Purdon, Scott McNeal, R Salonen, Alan Metz, Peter E. Coates	2001	31
8	The Effects of Supratherapeutic Doses of Duloxetine on Blood Pressure and Pulse Rate Journal of Cardiovascular Pharmacology ·Michael A. Derby, Lu Zhang, Jill C. Chappell, Celedon Gonzales, J. Callaghan, Mark Leibowitz, Larry Ereshefsky, David Hoelscher, Philip T. Leese, Malcolm I. Mitchell	2007	30
9	O4–03–02: The gamma secretase inhibitor MK–0752 acutely and significantly reduces CSF Abeta40 concentrations in humans Alzheimer s & Dementia ·Laura Rosen, Julie A. Stone, Andrew Plump, Jinyu Yuan, Tim Harrison, Mary Flynn, Aimée Dallob, Catherine Z. Matthews, Donna Stevenson, Dennis E. Schmidt, Theresa Palmieri, Mark Leibowitz, Stanford S. Jhee, Larry Ereshefsky, Ronald M. Salomon, Greg Winchell, Mark S. Shearman, M. Gail Murphy, Keith Gottesdiener	2006	28
10	A Randomized, Double-Blind, Placebo-Controlled, Multicenter, 28-Day, Polysomnographic Study of Gabapentin in Transient Insomnia Induced by Sleep Phase Advance Journal of Clinical Sleep Medicine ·Sandy A. Furey, Steven Hull, Mark Leibowitz, Shyamalie Jayawardena, Thomas Roth	2014	25
11	Similarity of Insulin Detemir Pharmacokinetics, Safety, and Tolerability Profiles in Healthy Caucasian and Japanese American Subjects The Journal of Clinical Pharmacology ·S. S. Jhee, William H. Lyness, Patrick B. Rojas, Mark Leibowitz, Victoria Zarotsky, Lisbeth V. Jacobsen	2004	18
12	Co-ML: Collaborative Machine Learning Model Building for Developing Dataset Design Practices ACM Transactions on Computing Education ·Tiffany Tseng, Matt J. Davidson, Luis Morales‐Navarro, Jennifer King Chen, Victoria Delaney, Mark Leibowitz, Jazbo Beason, R. Benjamin Shapiro	2024	8
13	Dose Proportionality and the Effects of Food on Bioavailability of an Immediate-Release Oxycodone Hydrochloride Tablet Designed to Discourage Tampering and Its Relative Bioavailability Compared With a Marketed Oxycodone Tablet Under Fed Conditions: A Single-Dose, Randomized, Open-Label, 5-Way Crossover Study in Healthy Volunteers Clinical Therapeutics ·Almasa Bass, Jeffrey G. Stark, Glenn C. Pixton, Kenneth W. Sommerville, Cynthia Zamora, Mark Leibowitz, Robert Rolleri	2012	7
14	A Single-Dose, 3-Way Crossover Pharmacokinetic Comparison Between Immediate-Release Oxycodone Hydrochloride With Aversion Technology (IRO-A, Oxecta), IRO-A With Niacin, and Oxycodone Hydrochloride (Roxicodone) in Healthy Adults Under Fasting Conditions American Journal of Therapeutics ·Mark Leibowitz, Cynthia Zamora, Albert W. Brzeczko, Jeffrey G. Stark	2012	7
15	Dihydroxyphenylglycol as a Biomarker of Norepinephrine Transporter Inhibition by Atomoxetine Journal of Clinical Psychopharmacology ·P. R. Bieck, Mark Leibowitz, D. Richard Lachno, Edouard Ledent, Robert Padich, S. S. Jhee	2016	6
16	Assessment of Pharmacokinetic Linearity and Relative Bioavailability of an Intranasal Diazepam Formulation Compared with Diazepam Rectal Gel in Healthy Adult Subjects (P02.214) Neurology ·Gary Bream, Mark Leibowitz, Bill Wargin, Kelly Abernathy, Herbert R. Henney, David Ward	2013	1

About Mark Leibowitz

Mark Leibowitz is a scholar working on Anesthesiology and Pain Medicine, Pharmacology, Psychiatry and Mental health, Emergency Medicine and Computer Science Applications, having authored 16 papers that have together received 522 indexed citations. Recurring topics across this work include Opioid Use Disorder Treatment (2 papers), Pain Management and Opioid Use (2 papers), Epilepsy research and treatment (2 papers), Receptor Mechanisms and Signaling (2 papers), Cholinesterase and Neurodegenerative Diseases (2 papers), Poisoning and overdose treatments (2 papers), Pharmacology and Obesity Treatment (2 papers) and Neuroscience and Neuropharmacology Research (2 papers). The work is most often cited by research in Pharmacology (185 citations), Psychiatry and Mental health (108 citations), Neurology (98 citations), Biological Psychiatry (14 citations) and Physiology (112 citations). Mark Leibowitz has collaborated with scholars based in United States, United Kingdom and Switzerland. Frequent co-authors include Larry Ereshefsky, S. S. Jhee, Heinz Schmidli, F. Pommier, Albert Enz, Gilbert Lefèvre, G Sędek, Silke Appel‐Dingemanse, Philip T. Leese and David Hoelscher. Their work appears in journals such as Journal of Cardiovascular Pharmacology, The Journal of Clinical Pharmacology, Neurology, Clinical Therapeutics and Alzheimer s & Dementia.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact